Active, not recruitingNot applicableNCT04922307
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
Studying Papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt University Medical Center
- Principal Investigator
- Kelvin MosesAssociate Professor
- Intervention
- Blood Sparing Protocol(procedure)
- Enrollment
- 240 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (3)
- H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04922307 on ClinicalTrials.govOther trials for Papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07586332INVESTIGATION OF THE GENETIC ETIOLOGY OF HERNIA SAC DEVELOPMENT IN MALE CHILDREN WITH UNDESCENDED TESTIS AND INGUINAL HERNIATrakya University
- RECRUITINGNCT06956144Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer PatientsThe First Affiliated Hospital of Xiamen University
- RECRUITINGNCT06532422Study of Post-operative Complications After Laparoscopic Outpatient NephrectomyGCS Ramsay Santé pour l'Enseignement et la Recherche
- RECRUITINGNANCT06542484The Real-world Treatment Satisfaction by Gefapixiant in RCCNagoya City University
- RECRUITINGPHASE3NCT06467097Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell CarcinomaSamsung Medical Center
- RECRUITINGPHASE4NCT05805436Preop Laxatives in Robotic Urologic SurgeryChad R. Tracy
- ACTIVE NOT RECRUITINGPHASE1NCT05704985Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsDEKA Biosciences
- ACTIVE NOT RECRUITINGPHASE2NCT05411081Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialNational Cancer Institute (NCI)